|
KMID : 0191120230380270205
|
|
Journal of Korean Medical Science
2023 Volume.38 No. 27 p.205 ~ p.205
|
|
|
Loss of Neutralizing Activity of Tixagevimab/Cilgavimab (Evusheld™) Against Omicron BN.1, a Dominant Circulating Strain Following BA.5 During the Seventh Domestic Outbreak in Korea in Early 2023
|
|
Yang Jin-Young
Hyeon Seok-Hwan
Baek Jin-Yang
Kang Min-Seo
Lee Keon-Young
Lee Young-Ho
Huh Kyung-Min
Cho Sun-Young
Kang Cheol-In
Choi Soo-Jeong
Peck Kyong-Ran
Lee Min-Sung
Lee Hye-Won
Kim Kwang-Wook
Hwang In-Su
Lee So-Yeon
Kim Byung-Chul
Lee Yoo-Kyoung
Ko Jae-Hoon
|
|
|
Abstract
|
|
|
|
Tixagevimab/cilgavimab is a monoclonal antibody used to prevent coronavirus disease 2019 among immunocompromised hosts and maintained neutralizing activity against early omicron variants. Omicron BN.1 became a dominant circulating strain in Korea early 2023, but its susceptibility to tixagevimab/cilgavimab is unclear. We conducted plaque reduction neutralization test (PRNT) against BN.1 in a prospective cohort (14 patients and 30 specimens). BN.1 PRNT was conducted for one- and three-months after tixagevimab/cilgavimab administration and the average PRNT ND50 of each point was lower than the positive cut-off value of 20 (12.9 ± 4.5 and 13.2 ± 4.2, respectively, P = 0.825). In the paired analyses, tixagevimab/cilgavimab-administered sera could not actively neutralize BN.1 (PRNT ND50 11.5 ± 2.9, P = 0.001), compared with the reserved activity against BA.5 (ND50 310.5 ± 180.4). Unlike virus-like particle assay, tixagevimab/cilgavimab was not active against BN.1 in neutralizing assay, and would not be effective in the present predominance of BA.2.75 sublineages.
|
|
|
KEYWORD
|
|
|
COVID-19, SARS-CoV-2, Evusheld, Neutralizing Antibody, BN.1 Variant
|
|
|
FullTexts / Linksout information
|
|
|
|
|
Listed journal information
|
|
|
|